Not only are PARP inhibitors proving to be an efficacious treatment for patients with metastatic breast cancer, but they're also improving quality of life, too.
When given an oral agent such as a PARP inhibitor, patients with metastatic breast cancer reported that they felt more in control of their life, something that Jennifer Litton, MD, of the The University of Texas MD Anderson Cancer Center Department of Breast Medical Oncology, called a “game changer.”
While these agents improve quality of life, they are also proving to be clinically efficacious, too. Both the EMBRACA trial (studying talazoparib in patients with metastatic breast cancer with a BRCA mutation) and the OLYMPIAD trial (studying olaparib for patients with metastatic breast cancer with a BRCA mutation) are showing that PARP inhibition therapy can improve treatment outcomes compared to standard-of-care chemotherapy in this patient population.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.